Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-24

Clinical Trial Update: A Trial to Determine the Efficacy and Safety of Presendin in IIH [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating Presendin for idiopathic intracranial hypertension was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Presendin

Snippet

Sponsor: Invex Therapeutics Ltd. | Conditions: Idiopathic Intracranial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2024-04-24